FindTrial
Sign In

Treatment of sepsis with acute respiratory distress syndrome with cilvelestat sodium

Efficacy and safety of cilvelestat sodium in the treatment of sepsis in patients with acute respiratory distress syndrome: a one-arm, before-and-after, self-controlled observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092186
Enrollment
Unknown
Registered
2024-11-12
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis with acute respiratory distress syndrome

Interventions

Case series:None

Sponsors

Deyang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: a. 18 years old <= aged <= 80 years old b. Diagnosed with sepsis according to Sepsis Guidelines SEPsis 3.0 and meeting the new 2023 ARDS global definition criteria c. Consent to participate in this study, patient's family members or patients voluntarily sign informed consent;

Exclusion criteria

Exclusion criteria: a. Terminal organ failure or malignant tumor b. Near death or expected to survive no longer than 72 hours c. Pregnancy or lactation d. There is a contraindication to the use of cilvelestat sodium or family members refuse to use cilvelestat sodium;

Design outcomes

Primary

MeasureTime frame
oxygenation index;—

Secondary

MeasureTime frame
Inflammatory indicators;Severity index of illness: Clinical pulmonary infection score, SOFA score, APACHEII score;Prognostic indicators: total duration of mechanical ventilation (h), 28 day survival rate, ICU length of stay (d), total length of stay (d);—

Countries

China

Contacts

Public ContactXie hong

Deyang People's Hospital

1173666507@qq.com+86 838 2418190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026